News | February 17, 2012

Latest Data Presented on 18F Amyloid Plaque Imaging Agent

Flutemetamol radiotracer images in normal patients and those with Alzheimers disease.

January 17, 2012 – Data presented at the 6th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that the investigational 18F imaging agent Flutemetamol could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions like Alzheimer’s disease. Flutemetamol is a GE Healthcare positron emission tomography (PET) radiotracer in phase III development for the detection of beta amyloid plaques.

Data presented in two abstracts from a clinical trial of 18F Flutemetamol in patients with suspected normal pressure hydrocephalus (NPH), a progressive condition associated with dementia, gait abnormalities and urinary incontinence, undergoing shunt placement, correlated Flutemetamol uptake with histopathological tissue biopsies for beta amyloid in vivo. In a third abstract from another study, researchers correlated Flutemetamol uptake and structural magnetic resonance imaging (MRI) in healthy volunteers and patients with a clinical diagnosis of Alzheimer’s disease or mild cognitive impairment (MCI). Specifically:

  • Flutemetamol uptake demonstrated a strong concordance with histopathology in subjects with NPH independent of timing and sequence of examinations.
  • Flutemetamol PET uptake showed 100 percent sensitivity and specificity with histopathology in a selected subset of subjects with NPH.
  • In a subset of patients with MCI, increased Flutemetamol uptake and decreased hippocampal volume were seen in those with progressive MCI versus those with stable MCI.

“These results support the potential role of Flutemetamol in helping physicians detect amyloid deposits in the brain,” said Jonathan Allis, MI PET segment leader, GE Healthcare Medical Diagnostics. “The ability to detect amyloid deposits in the brain could enable physicians to make a more accurate and earlier diagnosis of Alzheimer’s disease.”

The accumulation of beta amyloid in the brain may play a role leading up to the degeneration of neurons and is one of several biomarkers implicated in the development of Alzheimer’s disease. Currently, Alzheimer’s disease is confirmed by histopathological identification of tissue biomarkers, including beta amyloid plaques, in post-mortem brain samples.  Targeted imaging agents are being studied to determine their ability to help physicians detect amyloid deposition in live humans.

For more information: www.gehealthcare.com

 

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init